Jiangsu HengRui Medicine registers Phase 3 trial of SHR-3167 vs insulin degludec in type 2 diabetes
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll an estimated 680 participants and plans to start in November 2026. It is a multicenter, randomized, open-label Phase III trial comparing once-weekly SHR-3167 with once-daily insulin degludec over up to 33 weeks.
Primary source
ClinicalTrials.gov registry record, November 3, 2026
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Read the source: A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation